Treatment of HCV infection in Poland at the beginning of the interferon‐free era—the EpiTer‐2 study
- 6 January 2018
- journal article
- research article
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 25 (6) , 661-669
Abstract
Summary: The aim of the EpiTer‐2 study was to analyse patient characteristics and their medication for HCV infection in Poland at the beginning of the interferon‐free era. Analysis of data of HCV infected patients treated during the initial period of availability of interferon‐free regimens in Poland, who started therapy after 1 July 2015 and had available an efficacy evaluation report before 30 June 2017 was undertaken. A total of 2879 patients with chronic hepatitis C were entered, including 46% with liver cirrhosis. The most common was genotype 1b (86.8%). The study population was gender balanced, the majority of patients were overweight or obese and 69% presented comorbidities, with the highest prevalence that for hypertension. More than half of patients were retreated due to failure of previous therapy with pegylated interferon and ribavirin. Almost two‐third of patients received current therapy with ombitasvir/paritaprevir/ritonavir±dasabuvir (OPrD) ±ribavirin. Other patients received mostly sofosbuvir‐based regimens including combination with ledipasvir and pegylated interferon and ribavirin for genotype 3‐infected patients. Efficacy of treatment in the whole study population measured as intent‐to‐treat analysis was 95%. The most frequent regimen, administered for patients infected with genotype 1b, was 12 weeks of OPrD, resulting in an SVR rate of 98%. At least one adverse event was reported in 38% of patients, and the death rate was 0.8%. In conclusion, data from the EpiTer‐2 study confirmed the excellent efficacy and safety profile of the real‐world experience with recently introduced therapeutic options for genotype 1 HCV infection, but demonstrated weakness of the current therapeutic programme regarding genotype 3 infections.Keywords
Funding Information
- Polskie Towarzystwo Epidemiologów i Lekarzy Chorób Zakaźnych
This publication has 21 references indexed in Scilit:
- Effectiveness and safety of ledipasvir/sofosbuvir ± ribavirin in the treatment of HCV infection: The real-world HARVEST studyAdvances in Medical Sciences, 2017
- Effectiveness of hepatitis C antiviral treatment in a USA cohort of veteran patients with hepatocellular carcinomaJournal of Hepatology, 2017
- Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohortJournal of Hepatology, 2017
- Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antiviralsJournal of Hepatology, 2017
- Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling studyThe Lancet Gastroenterology & Hepatology, 2017
- Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antiviralsJournal of Hepatology, 2016
- Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: Data from three ANRS cohortsJournal of Hepatology, 2016
- Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapyJournal of Hepatology, 2016
- Efficacy of Sofosbuvir Plus Ribavirin With or Without Peginterferon-Alfa in Patients With Hepatitis C Virus Genotype 3 Infection and Treatment-Experienced Patients With Cirrhosis and Hepatitis C Virus Genotype 2 InfectionGastroenterology, 2015
- Effect of Peginterferon or Ribavirin Dosing on Efficacy of Therapy With Telaprevir in Treatment-Experienced Patients With Chronic Hepatitis C and Advanced Liver FibrosisMedicine, 2015